Table 2 – Description of Included Studies
Author, year | Study Type | Participant Description | No. Entered / Completed study | Follow up period | Intervention | Outcome measures |
|---|---|---|---|---|---|---|
Huang et al. [26] | OBS | AS patients with unilateral refractory AT enthesitis • M:F 6:1 • Disease Duration: 6.1 ± 5.7 years) | 12 entered/ 12 completed (12 AT). 7 treated with corticosteroid | 2,4,8 and 12 weeks | 7 patients injected with 1 ml betamethasone | o Pain o Entheseal thickness (US derived) o Bone erosion o Bursitis o Enthesophyte |
Srivastava & Aggarwal [27] | OBS | SpA patients with symptomatic AT enthesitis • M:F 8:1 • Subtypes: AS–10 JSpA–5 PsA–1 IBDA–1 USpA-1 | 29 patients (40 AT) entered/ 18 patients (27 AT) completed | 6 weeks | 20 mg methylprednisolone injected | o Pain o Entheseal thickness o Bone erosion o Bursitis o Enthesophyte o Entheseal hypoechogenecity (Doppler US) o Peritendinous oedema |